Aliskiren-chem-stru (Aliskiren Tablets 1)
Aliskiren Tablet, Film Coated
Product Images NDC 49884-424
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Aliskiren (NDC 49884-424). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Endo Usa, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Aliskiren (Aliskiren Tablets 2)
This document provides a list of drugs with the potential to interact with aliskiren, including inhibitors of the CYP3A4/P-gp enzymes, antihypertensive agents, and other medications such as statins and digoxin. The table shows the fold change and 90% confidence interval for the impact of co-administered drugs on the pharmacokinetics of aliskiren. Recommendations for each drug either suggest avoiding concomitant use or indicate no need for dose adjustment.*
Aliskiren (Aliskiren Tablets 3)
This document provides information on the impact of aliskiren on the pharmacokinetics of co-administered drugs through fold change and 90% CI. The drugs evaluated include antihypertensives, digoxin, metformin, atorvastatin, lovastatin, celecoxib, and warfarin. Based on the results, no dose adjustment is recommended for any of the drugs.*
Cntr-lbl-150mg (Aliskiren Tablets 4)
This is a medication containing Aliskiren Hemifumarate 165.765 mg, which is equivalent to Aliskiren 150 mg, in each coated tablet. Dosage instructions can be found in the package insert. It should be stored in a tightly closed container at 20° to 25°C to protect against moisture. The medication should be kept out the reach of children. The product is manufactured by Par Formulations Private Limited at a facility in India and distributed in the US by Par Pharmaceutical. The NDC number is 49884-424-11, and it comes in a package of 30 tablets.*
Cntr-lbl-300mg (Aliskiren Tablets 5)
This is a prescription drug with NDC code 49884-425-11. It contains 300mg of Aliskiren Hemifumarate equivalent to Aliskiren 300mg per film-coated tablet. It comes in a package of 30 tablets and is manufactured by Par Formulations Private Limited in India. The recommended dosage should be obtained from the package insert. It should be stored in a tightly closed container at 20°C to 25°C and protected from moisture. The drug should also be kept out of reach of children.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
